Monday, November 2, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1

Ascletis to Present Study Results of Oral Small Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Peptide Agonist ASC37 at ObesityWeek® 2026

MH
By Maren Holt · Senior Reporter, GLP-1
Nov 2 04:50 ETSource: Macau Business

From the source

Ascletis to Present Study Results of Oral Small Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Peptide Agonist ASC37 at ObesityWeek® 2026

Read at macaubusiness.com
Source URL https://macaubusiness.com/ascletis-to-present-study-results-of-oral-small-molecule-gipr-agonist-asc48-and-glp-1r-gipr-gcgr-triple-peptide-agonist-asc37-at-obesityweek-2026/
PeptiPrescribed peptides from $99/moSee all →